Randomized Phase II Study of Regorafenib in Refractory AOGC
John Zalcberg, PhD, medical oncologist, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses a randomized phase II study of regorafenib in refractory advanced oesophago-gastric cancer (AOGC).
Zalcberg says there was a significant improvement in progression-free survival (PFS) for patients who received regorafenib compared to placebo, with both arms receiving best supportive care. He and his team looked at Caucasian patients from Australia, New Zealand, and Canada compared to patients from Korea. The hazard ratio was .6 for the first group and .12 for the second.
Zalcberg and his colleagues hope to complete a phase III study in the near future, in order to define the benefit of regorafenib. Overall, the toxicities were not as significant as expected.
John Zalcberg, PhD, medical oncologist, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses a randomized phase II study of regorafenib in refractory advanced oesophago-gastric cancer (AOGC).
Ilson Examines Chemoimmunotherapy Regimens for Metastatic Gastroesophageal Cancers
December 20th 2024During a Case-Based Roundtable® event, David H. Ilson, MD, PhD, discussed the outcomes of the CheckMate 649, CheckMate 648, and KEYNOTE-859 trials of chemoimmunotherapy regimens in patients with upper GI cancers.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
